Join us for an insightful discussion on myelodysplastic neoplasms (or MDS) with Drs. DeZern and Mack as we review the current standards in diagnosis of MDS using cutting edge molecular techniques. This marrow failure syndrome requires thoughtful and accurate diagnosis to ensure appropriate risk assessment for clinical decision making. We will then review relevant therapeutic choices and how to monitor on and off therapy through the case of a 68 yo male with a 6-year history of disease. We will explore key diagnostic considerations, the distinct testing required for prognostication and the therapies available in lower and high-risk disease. This episode offers practical, evidence-based insights to enhance the recognition and management of MDS.Learning Objectives:Understand accurate diagnostic testing needed in MDS including core and aspirate, iron stain, IHC, and molecular diagnostics (MK and NGS)Review limited therapeutic options currently available in MDSDiscuss management strategies at each stage of this disease from lower risk to higher risk with suitable monitoring plansClinical Pearls:Comprehensive diagnosis and reassessment during disease course guide best practices for treatmentTreatment is warranted at phases of the disease with symptoms predominantly related to cytopenia

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related